Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

On November 6, 2026 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, reported new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in heavily pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The results were presented in a poster by Thomas U. Marron, MD, PhD, of the Tisch Cancer Center at Mount Sinai, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For patients with MSS mCRC whose cancer has progressed despite multiple treatments, treatment options remain limited, even among patients without active liver metastases. Historical studies of available later-line treatment regimens have reported median overall survival of approximately 10–14 months in relevant populations.1,2 Because survival beyond 18 months remains uncommon in this setting, the analysis defined long-term survivors as patients who lived at least 18 months after starting BOT+BAL.

The new SITC (Free SITC Whitepaper) analysis builds on previously reported results from the full 123-patient cohort, which demonstrated median overall survival of 21.2 months and a 33% estimated three-year survival rate, as presented at ESMO (Free ESMO Whitepaper) GI 2026 and published in Clinical Cancer Research. The current post-hoc analysis takes a closer look at the patients who achieved long-term survival, examining their clinical characteristics, the durability of their responses and factors that may help explain their outcomes.

The analysis found that 51% (63/123) of patients survived at least 18 months after starting BOT+BAL, including patients who had received prior immunotherapy and undergone several rounds of different treatment. Among the 63 long-term survivors, median overall survival had not been reached and an estimated 59% were alive at three years.

"For patients with metastatic MSS colorectal cancer without active liver metastases who have exhausted multiple therapies, living another year and a half or more is rare," said Thomas U. Marron, MD, PhD, of the Tisch Cancer Center at Mount Sinai and presenting author of the study. "What is particularly interesting is that the long-term survivors did not fit a single favorable clinical profile. Durable benefit was seen even in patients previously treated with immunotherapy, and a subset remains alive without any further cancer treatment. These findings suggest the potential to meaningfully change the course of disease and provide a compelling rationale for evaluating this approach earlier in treatment."

Clinical Characteristics and Outcomes of Long-Term Survivors

This post hoc analysis compared patients who survived at least 18 months after initiating BOT+BAL (n=63) with those who survived less than 18 months (n=60).

Broad patient characteristics: The two groups were generally similar across the characteristics examined including performance status, previous immunotherapy treatment, metastatic disease characteristics and several prognostic biomarkers.
Durable responses: Among long-term survivors, 35% (22/63) had a confirmed tumor response, including three complete responses in which tumors disappeared. Median duration of response was not reached, with responses lasting at least 37.4 months and 10 ongoing at the time of reporting. Patients in both the full cohort and long-term survivor group received a median of two BOT doses.
Time off treatment: Approximately 24% (15/63), or one in four long-term survivors, were alive and off all anticancer treatment at time of last follow-up. Of these patients, 13 had achieved tumor responses with BOT+BAL.
Prior treatment exposure: Long-term survivors were less likely to have received three or more prior lines of treatment, 56% (35/63) compared with 78% (47/60) of shorter-term survivors.
Safety Findings

No treatment-related deaths were observed. Immune-mediated adverse events occurred more frequently among long-term survivors than in the overall cohort. Immune-mediated diarrhea or colitis was the most frequently reported immune-mediated adverse event. Among long-term survivors who developed it, 97% (33/34) experienced resolution, with a median time to resolution of 13 days. Management included early corticosteroids and TNFα-directed therapy, when appropriate.

"The significance of these data extends beyond the survival milestone itself," said Steven J. O’Day, MD, Chief Medical Officer of Agenus. "Deep responses and durable disease control in heavily pretreated, immunologically cold tumors reinforce the potential of BOT’s differentiated Fc-enhanced immune-priming approach. The association between fewer prior therapies and long-term survival strengthens the rationale for evaluating BOT+BAL earlier in the course of disease. This is central to our Phase 3 ROBBIN strategy, which is designed to evaluate a short course of BOT+BAL before surgery in high-risk MSS colon cancer, with the goal of reducing recurrence, de-escalating the need for chemotherapy and increasing the potential for cure."

The full poster will be available at www.agenusbio.com/publications.

SITC 2026 Presentation Details

Title: Clinical Features of Long-Term Survivors Treated with Next-Generation Anti–CTLA-4 (Botensilimab) Plus Anti–PD-1 (Balstilimab) in Refractory Microsatellite-Stable Metastatic Colorectal Cancer

Presenter: Thomas U. Marron, MD, PhD; Tisch Cancer Center at Mount Sinai, New York, NY

Date: Saturday, November 7, 2026

Time: 10:00 a.m.–2:00 p.m. and 6:00–8:10 p.m. MST | 12:00–4:00 p.m. and 8:00–10:10 p.m. EST

Location: North Building, Lower Level, Exhibition Halls 4–5–6, Phoenix, Arizona

Poster Number: 472

BOT and BAL are investigational outside Armenia and are not approved by the U.S. Food and Drug Administration.

About the C-800-01 Study (NCT03860272)

C-800-01 (NCT03860272) is an ongoing, multicenter Phase 1b clinical trial evaluating botensilimab in combination with balstilimab across advanced solid tumors. The trial enrolled over 400 patients with refractory disease and included tumor types with limited or no responsiveness to prior checkpoint inhibitors. Endpoints included objective response rate (ORR), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).

The data presented at SITC (Free SITC Whitepaper) 2026 are from the MSS mCRC cohort, which included 123 patients without active liver metastases who received BOT 1 or 2 mg/kg every six weeks with BAL 3 mg/kg every two weeks. The primary endpoint was safety and tolerability. The present analysis retrospectively defined long-term survivors as those living at least 18 months from treatment start. Data cutoff was December 13, 2025.

(Press release, Agenus, NOV 6, 2026, View Source [SID1234674418])